|
C14ORF102 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62625468647093E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.31557045444242E-14 |
| Normal-vs-Stage2 |
5.643900E-04 |
| Normal-vs-Stage3 |
6.78335165815724E-12 |
| Normal-vs-Stage4 |
4.59632332194815E-12 |
| Stage1-vs-Stage2 |
2.394100E-02 |
| Stage1-vs-Stage3 |
5.391200E-01 |
| Stage1-vs-Stage4 |
1.973780E-02 |
| Stage2-vs-Stage3 |
1.597590E-02 |
| Stage2-vs-Stage4 |
7.849600E-04 |
| Stage3-vs-Stage4 |
7.762200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.9515946898282E-14 |
| Normal-vs-AfricanAmerican |
2.597900E-03 |
| Normal-vs-Asian |
3.17899995216919E-09 |
| Caucasian-vs-AfricanAmerican |
6.998100E-02 |
| Caucasian-vs-Asian |
7.060600E-01 |
| AfricanAmerican-vs-Asian |
3.743600E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.22597545635517E-12 |
| Normal-vs-Female |
1.64535052249448E-12 |
| Male-vs-Female |
7.401200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.81859971526421E-10 |
| Normal-vs-Age(41-60Yrs) |
3.59100527091982E-11 |
| Normal-vs-Age(61-80Yrs) |
1.64129998481144E-09 |
| Normal-vs-Age(81-100Yrs) |
2.618000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.077600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.001000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.863000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.399000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.694200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.007000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.095610E-02 |
| Classical-VS-Follicular |
6.226800E-01 |
| Classical-VS-Other |
1.160240E-01 |
| Classical-VS-Normal |
4.22650003883973E-09 |
| Tall-VS-Follicular |
1.718060E-02 |
| Tall-VS-Other |
4.987800E-01 |
| Tall-VS-Normal |
6.99720281716054E-11 |
| Follicular-VS-Other |
2.441700E-02 |
| Follicular-VS-Normal |
3.20149999954999E-07 |
| Other-VS-Normal |
1.76559999998105E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.26879950990144E-10 |
| Normal-vs-N1 |
3.70959929441028E-11 |
| N0-vs-N1 |
1.132310E-02 |
|
|
